Children are the future of the motherland and the hope of the family. According to the outline of China’s children’s development (2021-2030) issued by the State Council, the state will increase investment in children’s medical and health undertakings, integrate the concept of children’s health into economic and social development policies, and give priority to ensuring children’s health.
In a favorable policy environment, dyne pharmaceutical, as a leading enterprise in China’s pediatric medicine, has implemented the corporate mission of “making millions of Chinese children healthy and strong”. While continuing to focus on the R & D and innovation of special drugs for children, dyne pharmaceutical is also making efforts to reach users more efficiently and protect the health of more children.
On February 18, Dayin pharmaceutical and Jointown Pharmaceutical Group Co.Ltd(600998) Pharmaceutical Group held the signing ceremony of the 2022 strategic agreement. Yang Jie, President of Dayin Pharmaceutical Group and Liu Changyun, chairman of Jointown Pharmaceutical Group Co.Ltd(600998) Pharmaceutical Group, led their teams to attend the signing ceremony. The two sides will continue to work together to cooperate in terminal coverage, e-commerce cooperation, channel development, new product development, Brand Co Construction and other fields, Promote the flattening of commercial channels, chain and specialization of medical services, so that more children’s health products can reach users through Jointown Pharmaceutical Group Co.Ltd(600998) high-quality and comprehensive channel services.
join hands with the pharmaceutical circulation giant to make “reassuring children’s children’s drugs” accurately reach users
According to the data of the seventh national census, children under the age of 14 account for 17.95% of the total population in China. Among the 250 million children aged 0-14, suitable drugs account for only 2% – 6% of the total drugs. There is a huge market gap in children’s medication. On the other hand, the incidence of adverse drug reactions in children in China is twice that of adults and four times that of newborns. The difficulty and safety of drug use in children have become a national concern.
Dayin pharmaceutical has a voice in the development of pediatric medicine industry. In 2007, dyne pharmaceutical put forward the R & D concept of “tailor-made children’s drugs” for the pain points of the children’s drug industry, and built China’s first children’s drug technology R & D center in 2011. In 2013, dyne pharmaceutical was designated as the “children’s drug research base” by the economic information daily of Xinhua news agency.
Dayin pharmaceutical has performed well in the market of children’s nutritional supplements. Star products such as ikxin, gaidixin and yijiaxin have formed strong brand strength and user loyalty. At present, it is focusing on the research and development of children’s therapeutic drugs. There are 40 special drugs for children, involving 15 categories. During the 14th Five Year Plan period, 1 ~ 2 new products will be listed every year, A complete pediatric medication system has been gradually formed and is committed to solving the problems of accessibility and safety of medication for Chinese children.
It is precisely because of the difficulty of research and development, the large gap and the superposition of the impact of the epidemic that the limited resources need to be accurately reached. Therefore, dyne pharmaceutical has reached in-depth strategic cooperation with Jointown Pharmaceutical Group Co.Ltd(600998) group and gradually reshaped channels in pharmaceutical chain, e-commerce, grade hospitals, grass-roots medical treatment and other terminals. In 2021, dyne pharmaceutical was one of the 20 core suppliers of Jointown Pharmaceutical Group Co.Ltd(600998) group. Dyne products were operated in 28 provincial companies under Jointown Pharmaceutical Group Co.Ltd(600998) , accounting for 40% of dyne’s overall sales share.
At the signing ceremony, Xu Jintao, general manager of the terminal business department of Jointown Pharmaceutical Group Co.Ltd(600998) group, introduced the new Internet thinking tool and new business model. Yang Jie, President of dyne Pharmaceutical Group, said that Jointown Pharmaceutical Group Co.Ltd(600998) has been leading the development of the pharmaceutical circulation industry. The “focus, stability and innovation” proposed by Jointown Pharmaceutical Group Co.Ltd(600998) coincides with the business philosophy of dyne pharmaceutical.
It can be said that dyne pharmaceutical can be closer to users and achieve the flattening, efficiency and integrity of the marketing management system, which is inseparable from the channel advantages of Jointown Pharmaceutical Group Co.Ltd(600998) group. For Jointown Pharmaceutical Group Co.Ltd(600998) group, the cooperation with dyne pharmaceutical can also enrich children’s brand drugs, enrich the layout of the pharmaceutical field and stabilize its leading position in the pharmaceutical circulation industry.
fight side by side and continue to cultivate the field of children’s health
For dyne pharmaceutical, establishing deep cooperation with Jointown Pharmaceutical Group Co.Ltd(600998) group can not only empower channel management and credit, but also better support brand construction, innovative category education, integrate advantageous resources, reduce cost and increase efficiency, and form the same frequency resonance of upstream and downstream links of both sides.
At present, Dayin pharmaceutical and Jointown Pharmaceutical Group Co.Ltd(600998) cooperate in 13 categories. With the product layout of Dayin pharmaceutical in the field of children’s treatment and the multi product of yikexin brand, expand the product line to the fields of children’s treatment drugs, children’s health food, nutritional food and so on, and make great efforts to the layout of children’s great health industry with “children’s health care and treatment” as the core, Maintain strong potential energy output of product power and brand power.
In 2021, Dayin pharmaceutical achieved an operating revenue of 1.484 billion yuan and a net profit of 663 million yuan, an increase of 32.02% and 32.61% respectively over the previous year. This also means that Dayin pharmaceutical has adhered to deep cultivation in the field of children’s health for many years, has formed a benign and sustainable development, and has also condensed a strong sense of identity and trust in the minds of users.
In the face of the post epidemic era, users are constantly forming new consumption scenes. The re cooperation between dyne pharmaceutical and Jointown Pharmaceutical Group Co.Ltd(600998) group is like a house plot. In terms of safeguarding children’s health and transmitting health, the consistent and complementary enterprise philosophy of both sides is the foundation of win-win cooperation and mutual benefit.
